mHAM based drug for Osteoarthritis
mHAM orthopedics 1102 injectable
Mechanism of action
The aim is clinical developement of the Novel Osteoarthrosis Symptoms Drug, which significantly and immediatelly decrease a pain in joints affected area, simultaneously replaicing opioids, improve of join mobility and decrease of inflammation.
16% of Europe population suffere of Osteoarthritis. Two and half millions of them get TEP replacement / year with a cost of EUR 85B+ a year. In the past 5 years, the number of surgical operations in the endoprosthesis has increased by 80%. Rejection reaction or manifestation of hypersensitivity to the implant material is observed in 6 – 30% of cases of surgical intervention. Immune reaction is one of the causes of complications of bone tissue on implants.
USA is the number one consumer of narcotic drugs, with 40 240 defined daily dosages of opioids per million inhabitants per day. In second place is Germany with 28 862 defined daily dosages per 1 million inhabitants, followed by Canada with 26 029. The Netherlands is in ninth place, with 16 114 defined daily dosages per 1 million inhabitants.
Source: Data from the 2018 report by the International Narcotics Control Board, https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(19)30156-2/fulltext